^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug Class: | PARP inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative
Published date:
07/29/2021
Excerpt:
Patients with HR-positive MBC with germline BRCA mutations no longer benefiting from endocrine therapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy.
DOI:
10.1200/JCO.21.01374
